Ortho Clinical Diagnostics, ɗaya daga cikin manyan kamfanoni masu tsafta a duniya a cikin vitro, ya ba da sanarwar ƙaddamar da gwajin gwaji na farko na COVID-19 IgG da cikakken gwajin rigakafin COVID-19 nucleocapsid.
Ortho shine kawai kamfani a Amurka wanda ke ba da haɗin gwajin ƙididdigewa da gwajin nucleocapsid don dakunan gwaje-gwaje.Duk waɗannan gwaje-gwajen guda biyu suna taimaka wa ƙungiyar likitocin su bambance sanadin ƙwayoyin rigakafi da SARS-CoV-2 da sarrafa su akan tsarin amintaccen Ortho VITROS®.
Ivan Sargo, MD, Ortho Clinical Diagnostics, shugaban magunguna, asibiti da kimiyya ya ce "A Amurka, duk allurar rigakafin da aka yi an tsara su ne don samar da martanin rigakafin mutum ga furotin na kwayar cutar SARS-CoV-2.""Sabuwar gwajin rigakafin IgG na Ortho, tare da sabon gwajin rigakafin nucleocapsid, na iya samar da ƙarin bayanai don taimakawa tantance ko amsawar rigakafin ta fito ne daga kamuwa da cuta ta halitta ko kuma maganin rigakafin da aka yi niyya na furotin."1
Ortho's VITROS® Anti-SARS-CoV-2 IgG gwajin rigakafin ƙididdigewa shine gwajin rigakafin mutum na farko a cikin Amurka don samar da ƙimar ƙima bisa ga ƙa'idodin Hukumar Lafiya ta Duniya (WHO).2 Daidaitaccen gwajin rigakafin ƙwayar cuta yana taimakawa daidaita hanyoyin SARS-CoV-2 serological kuma yana ba da damar kwatanta bayanai iri ɗaya a cikin dakunan gwaje-gwaje.Wannan haɗe-haɗen bayanai shine mataki na farko na fahimtar haɓakawa da faɗuwar ƙwayoyin rigakafin kowane mutum da kuma tasirin cutar ta COVID-19 na dogon lokaci akan al'umma da kuma yawan jama'a.
Sabuwar gwajin ƙididdigewa ta Ortho ta IgG an ƙirƙira ta don ƙididdigewa da ƙididdige ƙwayoyin rigakafin IgG a kan SARS-CoV-2 a cikin jini da jini na ɗan adam, tare da ƙayyadaddun 100% da kyakkyawar azanci.3
Sabuwar Ortho ta VITROS® Anti-SARS-CoV-2 Total Nucleocapsid Antibody Test gwaji ne mai inganci 4 don tantance ingancin SARS-CoV-2 nucleocapsid a cikin marasa lafiya da suka kamu da kwayar cutar SARS-CoV-2 Antibody.
Chockalingam Palaniappan ya ce "Muna ci gaba da koyon sabon ilimi game da kwayar cutar ta SARS-CoV-2 a kowace rana, kuma Ortho ta himmatu wajen samar da dakunan gwaje-gwaje tare da ingantattun hanyoyin magance matsalolin da ke faruwa a yanzu da kuma nan gaba na wannan annoba ta ci gaba," in ji Dokta Chockalingam Palaniappan. , Babban Jami'in Innovation na Ortho Clinical Diagnostics.
Gwajin gwajin ƙima na Ortho na COVID-19 ya kammala aikin sanarwar amfani da gaggawa na Hukumar Abinci da Magunguna (FDA) ta Amurka (EUN) a ranar 19 ga Mayu, 2021, kuma ta ƙaddamar da izinin amfani da gaggawa (EUA) don gwajin ga FDA.VITROS® Anti-SARS-CoV-2 jimlar gwajin rigakafin nucleocapsid ya kammala aikin EUN a ranar 5 ga Mayu, 2021, kuma ya ƙaddamar da EUA.
Kuna son aika sabbin labaran kimiyya kai tsaye zuwa akwatin saƙo na ku?Kasance memba SelectScience yanzu kyauta >>
1. Marasa lafiya da aka yi musu allurar rigakafin cutar da ba a kunna ba za su samar da anti-N da anti-S antibodies.. ≥ 15 days bayan bayyanar cututtuka
Lokacin aikawa: Juni-22-2021